Biomarker Qualification Should Be Multi-Step Process, Regulators Say
Executive Summary
U.S. and European regulations expect qualification of biomarkers for clinical use to be a multi-stage process that incrementally broadens a marker's application
You may also be interested in...
FDA Expands Safety Signal Assessment With Mechanism-Based System
FDA will work with MolecularHealth Inc. to adapt the company’s software system, which combines molecular data with clinical data, to allow mechanism-based assessment of side effects.
FDA Drug Development Tool Guidance Leaves Door Open For Advisory Committee Reviews
FDA’s proposed process for qualifying drug development tools allows for the convening of advisory committee meetings or other public discussions about complicated submissions involving proposed biomarkers or patient-reported outcome instruments.
FDA Drug Development Tool Guidance Leaves Door Open For Advisory Committee Reviews
FDA’s proposed process for qualifying drug development tools allows for the convening of advisory committee meetings or other public discussions about complicated submissions involving proposed biomarkers or patient-reported outcome instruments.